CICC has released a research report reiterating its 'Outperform' rating on WUXI BIO (HKEX: 02269).

The firm maintained its profit forecasts and target price of HK$48, representing a potential upside of 44.0%.

This target implies adjusted P/E ratios of 27.8x and 23.7x for fiscal years 2026 and 2027, respectively, compared to the current share price multiples of 19.3x and 16.5x for the same periods.

Key Rationale Behind the Assessment

Management recently hosted a business update call, sharing the latest progress on its technology and development platforms and operational performance for the period from January to April 2026.

The company reaffirmed its 2026 revenue growth guidance of 13-17% year-over-year, or 16-20% excluding foreign exchange impacts.

It also updated its guidance for the next three years, targeting a 20% revenue CAGR and a 30% CAGR for its manufacturing segment, demonstrating confidence in its intrinsic value and business outlook.

Strong New Project Wins and Accelerating Commercialization

By the end of April 2026, the company had added 69 new projects, with approximately two-thirds originating from clients in Europe and the US.

Newly signed bispecific and multispecific antibody projects grew by over 50% year-on-year.

The total project portfolio expanded to 982, including 78 Phase III projects and 25 commercial projects, with the proportion of late-stage projects continuing to increase, providing a solid pipeline for future commercial scale-up.

Furthermore, the company added five 'Win-the-Molecule' projects, including two in Phase III, and anticipates that its top three manufacturing projects by revenue will each exceed $100 million in 2026.

Coupled with expectations for new Biologics License Application approvals, the certainty of commercial revenue growth is further enhanced.

Bispecific/Multispecific Antibodies as a Key Growth Driver

As of end-April 2026, the company had accumulated 211 bispecific/multispecific antibody projects, with 10 in Phase III and 3 already in the commercial stage.

The company expects to execute three Process Performance Qualification runs for such projects in 2026.

The report notes that the existing commercial bispecific antibody projects possess significant scale-up potential.

Additionally, nearly 20 research service projects in this area are expected to contribute future milestone payments and sales royalties.

Given the higher complexity and greater client switching costs associated with these advanced modalities, such projects typically offer higher profitability and retention rates, which is anticipated to enhance the company's revenue stability and commercial flexibility.

Strengthening Technological Edge and Competitive Moat

The company highlighted advancements in key platforms such as WuXia TrueSite and PatroLab.

The TrueSite platform, in particular, has shown strong performance, capable of shortening cell line development cycles and increasing average titers for monoclonal and bispecific antibodies.

It is also noted to reduce production costs by 30%-50% and lower capacity requirements by 30%-40%.

The report suggests that these platform capabilities are evolving from tools that improve R&D efficiency into core competitive advantages.

This is expected to continuously strengthen the company's global competitiveness in complex molecule fields like bispecifics, multispecifics, and biosimilars.

Potential Investment Risks

Key risks include geopolitical factors, slower-than-expected commercialization progress, challenges in new business expansion, and foreign exchange rate volatility.